Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Update on AMG 330 bispecific for R/R AML

Marion Subklewe • 14 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia AMG 330 Antibodies

Marion Subklewe, MD, of LMU Hospital Munich, Munich, Germany, discusses the preliminary pharmacokinetic data from the still-recruiting Phase I study of the bispecific CD3/CD33 antibody AMG 330 in relapsed/refractory acute myeloid leukemia (NCT02520427). This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Marion Subklewe

1:43
CD33-TIM3 dual CAR T-cells enhance specificity of AML treatment
Marion Subklewe • 9 Dec 2023
1:04
MP0533, a CD3-engaging DARPin, in R/R AML or MDS/AML: preliminary results of a Phase I/IIa trial
Marion Subklewe • 9 Dec 2023
1:42
Dose escalation of RO7283420, a HLA-A2-WT1 CD3 T-cell bispecific antibody, in R/R AML
Marion Subklewe • 9 Dec 2023
2:33
Novel immunotherapies in AML and insights into the future of the treatment landscape
Marion Subklewe • 9 Dec 2023

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals